760952-64-5 Usage
Uses
Used in Bioconjugation:
Mal-PEG1-acid is used as a bioconjugation agent for attaching biomolecules with thiol groups to other molecules or surfaces. The maleimide group forms a covalent bond with the thiol, providing a stable linkage.
Used in Drug Delivery Systems:
In the pharmaceutical industry, Mal-PEG1-acid is used as a component in drug delivery systems to improve the solubility, stability, and targeted delivery of therapeutic agents. The PEG spacer and terminal carboxylic acid facilitate the attachment of drugs or drug carriers, enhancing their bioavailability and efficacy.
Used in Diagnostics:
In the diagnostics field, Mal-PEG1-acid is used as a modifier to enhance the properties of diagnostic agents. The PEGylation can improve the solubility and circulation time of diagnostic molecules, while the maleimide group allows for the attachment of specific targeting ligands or imaging agents.
Used in Materials Science:
In materials science, Mal-PEG1-acid is used as a functionalizing agent to introduce biocompatibility, hydrophilicity, and reactive sites to various materials. The PEG spacer and maleimide group can be used to attach biomolecules or other functional groups to surfaces, creating materials with specific properties for applications in tissue engineering, sensors, or other areas.
Check Digit Verification of cas no
The CAS Registry Mumber 760952-64-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 7,6,0,9,5 and 2 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 760952-64:
(8*7)+(7*6)+(6*0)+(5*9)+(4*5)+(3*2)+(2*6)+(1*4)=185
185 % 10 = 5
So 760952-64-5 is a valid CAS Registry Number.
760952-64-5Relevant academic research and scientific papers
Fan, Shiyong,Li, Wei,Liu, Lianqi,Wang, Yanming,Xiao, Dian,Xie, Fei,Zhong, Wu,Zhou, Xinbo
, (2020)
Monomethyl auristatin E (MMAE) is the most popular and widely used cytotoxin in the development of antibody-drug conjugates (ADCs). However, current MMAE-based ADCs are all constructed using cleavable linkers, and this design concept still has insurmountable drawbacks. Their potential instabilities and lipophilic MMAE-induced “bystander effect” inevitably increase the toxicity to normal tissues. Herein, we overturn previous negative views of MMAE-based ADCs with non-cleavable linkers and propose using ionized L-Cysteine (Cys)-linker-MMAE as a novel payload, which can ingeniously enrich and enter tumor cells through receptor-mediated endocytosis of antibodies while its lower permeability helps to avoid further off-target toxicity. We demonstrate that Cys-linker-MMAE maintains high potency similar to free MMAE at the tubulin molecular level and can also be efficiently released in target cells. As a result, the preferred ADC (mil40-15) not only exhibits ideal plasma stability and maintains potent cytotoxicity as MMAE (IC50: 10?11 M), but also shows improved safety with lower bystander toxicity (IC50: 10?9 M), its maximum tolerated dose approaching the level of the naked antibody (160 mg/kg). This study indicated that Cys-linker-MMAE has the potential as a potent payload for ADCs, which is expected to provide novel strategies for the development of MMAE-based ADCs.
